Mentari Therapeutics names Todd Shegog to board, audit committee chair
MTRI•Mentari Therapeutics appointed Todd Shegog as a director and audit committee chair on November 9, 2026, following its merger with InMed Pharmaceuticals. Shegog has more than 30 years of experience in finance, operations, corporate strategy and compliance in the biotechnology and pharmaceutical industries.
1. Board appointment
Mentari Therapeutics appointed Todd Shegog as a director and audit committee chair on November 9, 2026, following its merger with InMed Pharmaceuticals. The company said he has more than 30 years of experience in finance, operations, corporate strategy and compliance in the biotechnology and pharmaceutical industries.
